Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

102 inhibitors Injecting

12th World AIDS Conference

+ patients and protease
(H/M) adults/Protease
n adherence/Protease
h reverse transcriptase
e to the use of protease
y prescribed/Protease
s treated with protease
s treated with protease
r reverse transcriptase
ethadone and protease
hoid cells/HIV infection
tance among protease
able access to protease
ity (ka) of HIV protease
7/The use of protease
pients/Use of protease
ct of the use of protease
/The effect of protease
nts receiving protease
normal now? Protease
pies including protease
and the use of protease
50/The use of protease
n HIV clinic/Protease
reased use of protease
ctivity of the protease
Chronic use of protease
actions during protease
e utilization of protease
okinetics with protease
herapy with protease

SKeyword
/Adherence re-framed in th
(PI) are associated with vii
and recreational drugs: a c
or combination therapy ar
/Factors which influence a
(PI) in the HIV+ homeless
/Peripheral insulin resistar
/Accumulation of gag-pol I
/The entry of 1592 (abaca,
in HIV-infected drug abuse:Carbohydrate-containing
in over 1,000 clinical HIV-1
/Ensuring equitable acces,
to a-1 acid glycoprotein/A
among HIV+ and AIDS per
in HIV+ Medicaid recipien
in newly diagnosed AIDSon the nutritional health of
in clinical practice: Results
and the end of consensus/
(PI): economical impact o
/Diabets, HIV infection, an
(PI) in HIV infected patient: Use and effects in an HIV
in HIV+ patients/Decreasi
on the HCV replication in
is associated with hormone
therapy/Adverse reaction
in AIDS patients in a publi
/Activity of Taxotere" (doc
(PI)/Comparison of viral Ic

Abstract -
ie big 32365
ral loa 32390
group 32391
nong 32399
dhere 32404
and 389*/32406
nce le 179*/41177
polypr 41184
vir) int 41192
ers/M 41202
biopo 41204
isola 230*/42195
s to pr 42226
Sfluor 42268
rsons 42300
ts/Us 42314
relate 42317
HIVi 42346
from 42403
AIDS 637*/44183
n opp 44247
dthe 60148:s ove 60388
clinic 60523
ed he 60578
HIV-c 60598
al abn 60648
s duri 60658
c AID 60754
etaxe 60934
)ad m 60992

sion in monocytic cells/ Inhibitory influences of a-MSH peptides o 60685
CR5 recycling - A novel mechanism of HIV infectivity/A 58*/11102
etwork embeddedness inhibits effectiveness of prevention efforts 14140
pressor protein p53 and apoptosis/HIV-1 Nef associates w 21148
alkaloid cepharanthine HIV-1 replication in chronically inf 60049
vitro/Human lactoferrin human immunodeficiency virus ty 60342
ephalin: a new cytokine HIV replication in PBMC/Methioni 60525
and toxicity of protease inibitor, containing regimens in HIV infect 12242
mates in Lagos, Nigeria/ Initial drug resistance tuberculosis among 13255
Study DMP 266-024)/ effectiveness and tolerability of nelfi 22386
ction drug users (IDU)/ viral load (VL) soon after seroconver 23396
e therapy after failure of protease inhibitor (PI) regimen/Effic 12330
e reasons of absence of virological response/Protease inhibi 12334
TG-076 protocol and its results in the largest ongoing perinat 12408
HIV-infected persons at primary care presentation and six m 14178
arinii pneumonia as an AIDS indicator disease among adult 22185
S patients in 1996/The opportunistic infection (01) among Si 22332
nd nevirapine (NVP) as antiretroviral therapy and following tr 22357
IDS patients, following protease failure/Long-term viral sup 32295: Analysis according to serum vitamin A levels/Survival and 42363
cleoside analogues as antiretroviral therapy: A cohort study 60411
o Canada following an HIV viral load test/Evaluating the ap 60670
egimens according to CD4 count/Virological response to p 60812
V-1 can recombine and initiate a spreading infection/Infectious m 11161
ors of young and recent injection drug users in New York Ci 23228
Is without wasting who maximally suppressive antiretrovir 32183
ession during tritherapy initiated at primary HIV-1 infection/Full co 22384
ng young adult recently injection drug users (the REACH I 23168
nd young adult recently injection drug users (the REACH I 23191
g adults who recently injection drug use in the Risk Eval 33394
o overseas populations by the French Ministry of Health/I 34213
ehaviors among new initiates into injection drug use over 40 ye 23176
s living with HIV/AIDS/ Initiating the population on the individual f 33511
bacterial infection after of highly active antiretroviral ther 22172
8+ T cell oligoclonality/ of antiretroviral therapy during pr 109*/31121
king in general practice/ of antiretroviral treatment: Decisi 60310
ons in the dimerization site can restore viral replication/ 378*/11126
on-homologous dimer sequence found in different subt 11161
s in HIV(+) women after of protease inhibitor therapy/Ch 177*/12373
scussions about sexual: Reducing the impact on peer no 14138
e United States/Age of of sexual intercourse among hig 14329
vir-SGC, d4T and ddC) in previously untreated patients ( 21123
ease progression after of protease-inhibitors therapy: A 22257
ntenance therapy after of HAART in 4 AIDS patients/Lo 22268
infected patients/Early of antiretroviral therapy normaliz 32320
et youth/Drug injection among street youth/Drug injecti 33347
dictors of drug injection in a street youth cohort/Predictor 33389
HIV viremia/Treatment during PHI but not in chronic infe 42164
treatment centre: CSF modalities and impact on anti-inf 42436

- Keyword Abstract --
cs associated with late of health care in patients with HI 42456
disease associated with of protease inhibitor therapy/Thr 60160
nitis associated with the of effective antiretroviral therapy 60505
ia syndrome after haart /Accelerated opportunistic infecti 60999
H/A on the Pilly Lutaaya Initiative - PLWH/A project/Income gener 34278
of a South African NGO /Community-based home-based 12427
/Developing a training to support midwives in implemen 13566
n home based care/An to strengthen home based care/ 22448
DS economic research /Costing HIV/AIDS: The Canadia 480*/24122
nd health care reform in Thailand/HIV/AIDS epidemic 24143
rs (MATEP) adherence: Rationale and goals/The Midwe 32381
e in a vaccine education /Videotape in a vaccine educatio 33455
e prevention marketing demonstration sites/Breaking m 33456
nch ministry for health's /Improvement and rationalization 33495
ict expanded response (DRI): Missing link in HIV/AIDS c 34110
Faso/District response (DRI): Fostering partnership in HI 34127
mission in Brazil: A EU to support key prevention project 43209
HIV prevention: A WHO /Drug substitution treatment for H 43266
CDC African-American: Keeping pace with an unrelentin 43279
AIDS NGOs consortium /HIV/AIDS policy development a 43566
he APN+ human rights /Training HIV positive people to d 535*/44133
IDS Trust employers' (NAT EI)/The National AIDS Tru 44171
idemic/The HIV action: A collaborative model for catalyz 44222
IDS a local government /Creating an employment opport 44300
nd Mexico develop joint initiatives on HIV affected families/Model 44259
DS care and prevention /Youth in peer group HIV/AIDS 60007
enting government-led in drug prevention/Addressing 60140
sex with men and also inject drugs (MSM-IDU) in Denver/The rel 23406
sex with men and also drugs (MSM-IDU): A profile of the gr 23550
uction programmes for injectable drug users in Porto Alegre - An 23230
/Use of the long-acting contraceptive Depo Provera an 23462
in macaques and mice injected with alvac-HIV (vCP205)/Kinetic 11242
and TB Associated with Injecting Drug Use and Resistant M.tb, Ba 616*/13264
gnitable HIV epidemic/ drug use in Dhaka, Bangladesh: 23215
ery large HIV epidemic: drug users in New York City, 199 584*/23216
fection associated with drug use: An overview/Strategie 43308
n central London gyms/ behaviour among gay men using 60811
tease inhibitors among drug users in Amsterdam: Cumul 12291
a prospective cohort of drug users (IDUs) in Bangkok, T 13127
e HIV epidemic among drug users in Bangkok, Thailand 13129
btypes of HIV-1 among drug users in southern China/E 13131
pe B and E strains from drug users (IDUs) in Bangkok, T 13133
btypes B' and E among drug users (IDUs) in Bangkok, T 13144
ce trends of HIV among drug users in northern Italy, 1990 13185
tis B/C infection among drug users in Europe/HIV and he 13192
s B and C virus among drug users admitted to drug treat 13224
d and CD4 cell count in drug users (IDUs) newly infected 191*/13302
ression in HIV infected drug users/Lack of evidence for 13304
oin on CD4+ decline in drug users/New evidence to rec 13334
4 HIV-1 seroconverted drug users in Europe?/Geograp 192*/13338
in users/Transitions to and seroconversions for HIV, he 13382
nd condom use among drug users/Temporal trends in th 14112
dation of statements by drug users (IDUs) based on the a 14114
or fast diagnosis of the drug use and its health conseque 14302
e viral infections among drug users in Russia/Prevalence 22212
Sexual risk behaviors of drug users in Bangkok, Thailand 23154
eroconversions among drug users participating in a HBV 23169
ion among persistently drug users/Methadone mainten 23179
fection associated with drug use/Assessing and respon 23188
s importance/Residual risk in Amsterdam is often deliber 23193
and syringe sharing by drug users in England and Wales 23199
volution of care among drug users in Residential Rehabil 23201
g risk behaviors among drug users (IDUs)/Projeto Brasil 23208
g HIV risk factor among drug users in Bangkok/Incarcera 23209
smokers in a sample of drug users, in Rio de Janeiro, Br 23212
to HIV infection among drug users in Vietnam/Awarene 23213
valence among female drug users (IDU) in London, 199 585*/23214, Mexico/Persons who drug in treatment and prisoners i 23218
among Basque Country drug users (IDUs): 1992-1996/B 23224
rs amongst uninfected drug users?/ls a voluntary confid 23234
g risk behaviors among drug users in the Rhode Island N 23236
viour and prevention for drug users: Are women more at ri 23239
iral infections among drug users in Zurich, Switzerland 23352

rkers with no history of drug use, in New York city/Fellati 23407
smission of HIV among drug users (IDUs) along the US- 24103
ansmission in Mexican drug women/HIV risk transmissi 24106
terile needles among drug users admitted to drug treat 33197
ng"/Phase II: Attending drug users (IDUs) - Creating a "s 33293
rough outreach among drug users in Manipur, India/Beh 33349
V prevention project for drug users/Harm reduction need 33393